Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.82 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | ITGA1 | P56199 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 2/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | IL1RN | P18510 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30209693 | 0.91 | POLB (0.94) | POLBPFKFB3MAPTAKR1C3MEN1 | |
| SCHEMBL2888070 | 0.91 | POLB (0.94) | POLBPFKFB3MAPTAKR1C3MEN1 | |
| SCHEMBL30702318 | 0.90 | PFKFB3 (0.76) | POLBPFKFB3MAPTAKR1C3MEN1 | |
| SCHEMBL4063367 | 0.90 | PFKFB3 (0.76) | POLBPFKFB3MAPTAKR1C3MEN1 | |
| SCHEMBL30702319 | 0.90 | PFKFB3 (0.76) | POLBPFKFB3MAPTAKR1C3MEN1 | |
| SCHEMBL787677 | 0.90 | PFKFB3 (1.00) | POLBPFKFB3MAPTAKR1C3MEN1 | |
| SCHEMBL2241495 | 0.88 | ITGA1 (0.80) | POLBPFKFB3MAPTAKR1C3MEN1 | |
| SCHEMBL17331335 | 0.88 | POLB (0.78) | POLBPFKFB3MAPTMEN1KMT2A | |
| SCHEMBL11025715 | 0.88 | POLB (0.78) | POLBPFKFB3MAPTMEN1KMT2A | |
| SCHEMBL10386045 | 0.87 | POLB (0.64) | POLBPFKFB3MAPTAKR1C3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701627-B2 | LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-06-15 | — | — | US | disclosed |
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-06-15 | — | — | US | disclosed |
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE | 2015-12-17 | — | — | US | disclosed |
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE | 2015-12-17 | — | — | US | disclosed |
| CN-102395270-B | Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same | FASGEN INC | 2014-11-12 | — | — | CN | disclosed |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2013-02-07 | — | — | US | disclosed |
| US-20120232104-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD (DE) | 2012-09-13 | — | — | US | disclosed |
| CN-101189210-B | Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (L-CPTl) inhibitors | HOFFMANN LA ROCHE | 2012-06-06 | — | — | CN | disclosed |
| US-20120083471-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same | FAS SECURED CREDITORS HOLDCO, LLC | 2012-04-05 | — | — | US | disclosed |
| EP-0831800-A1 | ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THE USE THEREOF AS FACTOR Xa INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996040100-A1 | ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THE USE THEREOF AS FACTOR Xa INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0159291-A1 | Ink composition for the ink-jet printing process | CIBA-GEIGY AG (CH) | 1985-10-23 | — | — | EP | disclosed |
| US-4501747-A | ANTIHISTAMINES | SANOFI (FR) | 1985-02-26 | — | — | US | disclosed |
| US-4439444-A | HISTAMINE RECEPTOR ANTAGONISTS | SANOFI (FR) | 1984-03-27 | — | — | US | disclosed |
| EP-0103503-A2 | N-substituted amides, their salts, process for their preparation and pharmaceutical compositions containing them | SANOFI S.A. (FR) | 1984-03-21 | — | — | EP | disclosed |
| EP-0094303-A1 | Amides, their salts, process for their preparation and pharmaceutical compositions containing them | SANOFI S.A. (FR) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | LRRK2, PARK7, SNCA | POLB 2683/4885PFKFB3 3497/4885MAPT 42/4885 |
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, CD44 | POLB 356/4885PFKFB3 3003/4885MAPT 2835/4885 |
| US-20120232104-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | POLB 2805/4885PFKFB3 509/4885MAPT 2667/4885 |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, CD44 | POLB 356/4885PFKFB3 3003/4885MAPT 2835/4885 |
| US-20120083471-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same | LCAT, DGAT2, SOAT2 | POLB 4026/4885PFKFB3 1114/4885MAPT 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.